Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04488601 · ClinicalTrials.gov registry record · Phase 2
Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study
A Phase 2 study, sponsored by AgelessRx.
- Completed
- Registry status
- Phase 2
- Development phase
- 129
- Enrollment target
NCT04488601 is a Phase 2 study that has completed, run by AgelessRx. The registered enrollment target is 129 participants.
The verdict
NCT04488601, a Phase 2 study, has completed, sponsored by AgelessRx.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 129 participants
- Enrollment target
Study Summary
This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.
Interventions
- DRUG Placebo
- DRUG Rapamycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 129 participants |
| Start Date | 2020-01-01 |
| Est. Completion | 2023-12-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04488601
The ClinicalTrials.gov registry entry for NCT04488601 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 129 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AgelessRx, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT04488601 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04488601 about?
NCT04488601 is a clinical study titled "Participatory Evaluation (of) Aging (With) Rapamycin (for) Longevity Study". This is a randomized, placebo-controlled trial into the safety and efficacy in reducing clinical measures of aging in an older adult population.
What is the current status of trial NCT04488601?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 129 participants. The study started on 2020-01-01. Estimated completion is 2023-12-30.
What interventions are being tested in trial NCT04488601?
The interventions under investigation include: Placebo (DRUG), Rapamycin (DRUG).
Who is sponsoring clinical trial NCT04488601?
This trial is sponsored by AgelessRx, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.